CVI Welcomes Clinical Trials Manager Edward Finn

The Stanford Cardiovascular Institute (CVI) welcomes Clinical Trials Manager Edward Finn. He started in this role in March of 2013. Ed provides support to CVI members and their interdisciplinary clinical trials research; this support includes the recruitment, screening and consenting of patients, IRB submission, site initiation and monitoring visits, database management, budgeting, billing, and overall study coordination.

Ed has a Master’s degree from San Francisco State University in Sport Science; his thesis work focused on diabetes and cardiovascular disease. He has been working as a data analyst and research coordinator since 2005, having formerly worked at the VA, PAMF, Stanford University, and TempusClinic. 

Ed is working with Dr. Ronald Dalman on a Medtronic PAN registry that is currently recruiting patients with Cardiac Rhythmic disorders and recently opened a new arm to Cardiovascular therapy (heart valves).

Ed is also working on 3 stem cell trials: 

1) Dr. Phillip Yang and Dr. Nicholas Leeper’s PACE trial (associated with the CCTRN), which is currently recruiting PAD patients with intermittent claudication for treatment with ALDH bright cells; 

2) Dr. Joseph Wu’s phase II Amorcyte Neostem trial, which is recruiting up to 221 subjects through 61 sites nationwide to investigate the preservation of cardiac tissue with autologous CD34+ stem cells for the treatment of acute MI; and 

3) Dr. Joseph Wu’s phase IIb Aastrom trial, which is currently recruiting 108 subjects to investigate a treatment of Chronic Heart Failure with ixmyelocel –T stem cells. 

If you would like more information about how Ed can help with your clinical trials, please contact him at efinn@stanford.edu or (650) 724-6167.